What is known
What is new
Introduction
Methods
Retrieval strategy
Literature inclusion and exclusion criteria
Literature screening and data extraction
Literature quality evaluation
Evidence quality evaluation process
Criteria for determining evidence level and recommendation level
Expert consultation
Data analysis
Results
Selection process and general characteristics of the included articles
Articles | Author/Institution/Organization | Year | Country | Source | Tools for evidence grading and recommendation strength |
---|---|---|---|---|---|
Guideline 1 [28] | Hartman et al | 2018 | Israel, United Kingdom, Hungary, China, etc | Web of Science | GRADE |
Guideline 2 [2] | Monagle et al | 2018 | Australia, Canada, Mexico, United States, etc | PubMed | GRADE |
Guideline 3 [29] | Sibson et al | 2018 | United Kingdom | Web of Science | GRADE |
Guideline 4 [30] | ASCO | 2013 | United States | GIN | Jadad |
Guideline 5 [31] | Expert Committee of Guidelines for Prevention and Treatment of Thrombotic Diseases in China | 2018 | China | CNKI | GRADE |
Guideline 6 [32] | American College of Chest Physicians | 2012 | United States | BMJ best practice | GRADE |
Guideline 7 [33] | Working group on evidence-based guidelines for clinical practice of intravenous infusion therapy in children | 2021 | China | CNKI | GRADE |
Systematic review 1 [34] | Barco et al | 2017 | Netherlands, Germany | Web of Science | — |
Systematic review 2 [35] | Brandão LR, Shah N, Shah PS | 2014 | Canada | The Cochrane Library | — |
Systematic review 3 [36] | Schoot et al | 2013 | Netherlands | The Cochrane Library | — |
Systematic review 4 [37] | Shah PS, Shah N | 2014 | Canada | The Cochrane Library | — |
Systematic review 5 [38] | Sharathkumar et al | 2020 | United States, United Kingdom, Canada, Austria, Israel | Web of Science | — |
Systematic review 6 [39] | Wang et al | 2020 | China | CNKI | GRADE |
Systematic review 7 [40] | Tian et al | 2020 | China | Web of Science | — |
Expert consensus 1 [41] | Ewenstein et al | 2004 | United States | Web of Science | The rating system adopted has been modelled on that of the US Centers for Disease Control and Prevention (CDC) |
Expert consensus 2 [13] | Giordano et al | 2015 | Italy | Web of Science | Infectious Diseases Society of America (IDSA) -United States Public Health Service grading system for ranking recommendations |
Expert consensus 3 [42] | ITAC-CME | 2013 | International | Medlive | GRADE |
Expert consensus 4 [43] | Expert Committee of Thrombosis and Vascular Special Fund of China Health Promotion Foundation | 2020 | China | Medlive | — |
Expert consensus 5 [44] | Shanghai Cooperation Group on Central Venous Access; Expert Committee on Vascular Access, Committee of Experts on Focused Diagnosis and Treatment of Solid Tumors, Shanghai Anti-Cancer Association | 2019 | China | Medlive | — |
Expert consensus 6 [3] | Chinese Chapter of the International of Angiology; Peripheral Vascular Disease Chapter, Chinese Geriatrics Society | 2020 | China | Medlive | — |
Expert consensus 7 [45] | Chinese College of Interventionalists | 2019 | China | Medlive | — |
Expert consensus 8 [46] | Zhejiang Implantable Venous Access Port Collaboration Group( ZIVAPCG) | 2018 | China | CNKI | — |
Expert consensus 9 [47] | The Expert Group on Safety Management o f Central Venous Access Device | 2020 | China | Medlive | GRADE |
Quality evaluation results of the included articles
Quality evaluation results of the guidelines
Guideline | ICC | 95%CI | F | P |
---|---|---|---|---|
Guideline 1 [28] | 0.914 | (0.838,0.959) | 32.611 | 0.000 |
Guideline 2 [2] | 0.858 | (0.738,0.932) | 20.612 | 0.000 |
Guideline 3 [29] | 0.898 | (0.807,0.952) | 29.449 | 0.000 |
Guideline 4 [30] | 0.786 | (0.602,0.897) | 14.572 | 0.000 |
Guideline 5 [31] | 0.840 | (0.712,0.922) | 16.400 | 0.000 |
Guideline 6 [32] | 0.923 | (0.845,0.965) | 42.887 | 0.000 |
Guideline 7 [33] | 0.804 | (0.640,0.906) | 15.480 | 0.000 |
Guidelines | Percentage of field standardization (%) | ≥ 60% field number (n) | ≤ 30% field number (n) | Recommendation level | |||||
---|---|---|---|---|---|---|---|---|---|
Scope and object | Participant | Rigor | Clarity | Application | Independence | ||||
Guideline 1 [28] | 62.96 | 62.96 | 84.03 | 92.59 | 25.00 | 72.22 | 5 | 1 | B |
Guideline 2 [2] | 87.04 | 96.30 | 69.44 | 88.89 | 87.50 | 77.78 | 6 | 0 | A |
Guideline 3 [29] | 64.81 | 24.07 | 68.75 | 87.03 | 25.00 | 97.22 | 4 | 2 | B |
Guideline 4 [30] | 92.59 | 87.03 | 92.36 | 88.89 | 47.22 | 100 | 5 | 0 | B |
Guideline 5 [31] | 88.89 | 87.04 | 68.75 | 88.89 | 27.78 | 72.22 | 5 | 1 | B |
Guideline 6 [32] | 75.93 | 33.33 | 46.52 | 90.74 | 29.17 | 83.33 | 3 | 1 | B |
Guideline 7 [33] | 81.48 | 88.89 | 85.42 | 96.30 | 56.94 | 97.22 | 5 | 0 | B |
Mean | 79.10 | 68.52 | 73.61 | 90.48 | 42.66 | 85.71 | — | — | — |
Quality evaluation results of systematic reviews
Quality evaluation results of expert consensuses
Summary and localization of the best evidence for CRT preventive care in hospitalized children
Topics | Subtopics | Recommendations | Tools | evidence level | recommendation level |
---|---|---|---|---|---|
Personnel qualification and quality management | Responsible Team | 1. For pediatric specialty hospitals, it is recommended to construct a pediatric intravenous access management team. For comprehensive hospitals with pediatric specialties, there must be pediatric nurses playing a role in the intravenous access management team at least. If the comprehensive hospital has large pediatric departments (100 beds), a separate pediatric intravenous access management team can also be considered [33] | GRADE | D | Strong |
2. The placement, use and maintenance of CVAD should be conducted by qualified and trained professionals [47] | GRADE | D | Strong | ||
Personnel Training | 3. It is recommended to establish a nurse training system to prevent CRT blockage [47] | GRADE | B | Weak | |
4. It is recommended to develop evaluation indicators for the core competency of the use and maintenance of CVAD, conduct systematic theoretical courses, formulate standard operating procedures, and implement rigorous assessment and evaluation, to improve the quality of training [47] | GRADE | B | Strong | ||
Quality control | 5. It is recommended to set up an intravenous infusion safety management committee, develop a perfect infusion management system, and establish quality control systems such as an intravenous infusion transmission network system, to reduce the occurrence of catheter-related complications [47] | GRADE | A | Strong | |
Pediatric patient selection | 6. CVADs should be reserved only for the medical needs of individual pediatric patients [41] | CDC | D | Weak | |
7. CVAD placement should remain for individuals whose families express a willingness and commitment to master the required skills and are expected to exercise diligence in the care of the CVAD [41] | CDC | C | Strong | ||
Risk assessment | 8. Caregivers and healthcare professionals should maintain a great suspicion index for the presence of CRT [41] | CDC | A | Strong | |
9. Pediatric CRT diagnosed on the basis of ultrasound is usually asymptomatic [33] | GRADE | B | Strong | ||
10. Thrombotic and bleeding risk assessments are recommended for children who need CVAD [43] | JBI | 5b | Strong | ||
11. In the development of pediatric CRT, non-tunneled catheters, and antibiotic therapy are protective. History of thrombosis, gastrointestinal/liver disease, hematologic disease (e.g., ALL), tumors, sepsis, hemodialysis, ECMO, cardiac catheterization, PN/TPN, PICC placement (compared to tunneled catheters and PORT), femoral vein placement (compared to subclavian vein placement), multiple catheters, multiple catheter lumens, CLABSI, catheter dysfunction, and long-term indwelling catheter are risk factors [39, 40, 43] | GRADE | D | Strong | ||
12. Routine screening for thrombotic disease is currently not warranted until the first CVAD is placed, unless the individual has experienced a catheter-independent thromboembolic event [41] | CDC | A | Strong | ||
CVAD selection and use | Size | 13. The infusion device with the least number of lumens and the minimum diameter should be selected under meeting the therapeutic needs [3] | JBI | 5b | Strong |
14. Catheters should be selected according to the conditions of the vessel to be placed, and the recommended ratio of the outer diameter of catheter to the inner diameter of the placed vein is ≤ 0.45% [3] | JBI | 3c | Strong | ||
Type | 15. PICC could be selected for neonates, very low and ultra-low birth weight infants [47] | GRADE | A | Strong | |
16. For children requiring a CVAD and at a high risk of CRT, an internal device (PORT) should be prioritized over an external tunneling device (Hickman or Broviac catheter) [29] | GRADE | B | Weak | ||
17. Until further pediatric data are available, we recommend that tunneled lines can be preferred to PICC in children with cancer where feasible [29] | GRADE | B | Weak | ||
18. It is suggested that children with chronic kidney disease (whether or not they are in the end-stage) should consult with the physician about the plan of hemodialysis vascular access before indwelling the catheter, and determine the location and type of catheter after a thorough weighing of the pros and cons [3] | JBI | 5b | Strong | ||
Site | GRADE | B | Strong | ||
Puncture | 20. Ultrasound-guided puncture is recommended for central venous catheterization [33] | GRADE | C | Strong | |
21. Ultrasound-assisted internal jugular vein puncture is preferred for PORT. Localization with the help of an X-ray is recommended. For neonates, echocardiography and electrocardiography can also be used [44] | JBI | 3d | Strong | ||
22. The recommended location of PORT placed into the child is below the clavicle and above the 5th intercostal space [33] | GRADE | D | Weak | ||
Fixation | 23. It is suggested CVAD be secured with complete dressings, StatLock, polyurethane clear dressings, or tissue adhesives [33] | GRADE | D | Strong | |
Time | 24. For children with ALL, it is not necessary to delay CVAD placement until the termination of ALL induction therapy. The decision regarding placement timing should also consider the physical and psychological consequences of delayed placement in individuals with poor venous access [29] | GRADE | B | Weak | |
Tip position | 25. The safest location of the tips is the junction of the superior vena cava and the superior wall of the right atrium. For CVADs placed in the lower extremities, the tips should be located above the diaphragm in the inferior vena cava. For newborns and infants under 1-year-old, the tips should be avoided into the heart [3, 13, 41, 42] | GRADE | A | Strong | |
26. Non-infectious complications of PICC would occur if the tip is not in a central position [33] | GRADE | D | Strong | ||
27. Catheters with ectopic tips should be adjusted to a central position before continued use [3] | JBI | 5b | Strong | ||
28. The end of the PORT catheter in children should be located in the inferior segment of the superior vena cava, not exceeding the junction of the superior vena cava and the right atrium, and roughly 1.5 vertebrae below the augmentation on the chest radiograph [45] | JBI | 3d | Strong | ||
GRADE | D | Strong | |||
Catheter maintenance | Flushing/sealing | GRADE | C | Weak | |
31. Applying the flushing/sealing technique correctly. The catheter should be clamped and the syringe should be separated in sequence to reduce blood reflux. Drug compatibility shall be checked when infusing ≥2 drugs simultaneously, and flushing the line adequately with 0.9% sodium chloride solution or changing the infusion set before each infusion [3] | JBI | 5b | Strong | ||
PORT maintenance | 32. Maintaining catheters regularly as required, flushing properly and timely, and sealing with urokinase when a thrombosis occurred [46] | JBI | 2d | Strong | |
33. Flushing catheters in the sequence of "isotonic saline - drug injection - isotonic saline - heparin solution" and keeping the bevel of the non-invasive needlepoint flushed in the opposite direction of the exit to maintain the PORT patency [47] | GRADE | D | Weak | ||
34. Generally choose a 24 G non-invasive needle. Using a syringe >10 ml when flushing/sealing. Confirming the patency when drawing back the blood, and determining causes if no blood is returned. Using Saline in pulse style to flush catheters and diluted heparin solution to seal the lines under positive pressure. Routine maintenance should be carried out if the PORT is not used for 1 month in the treatment intervals [45] | JBI | 5b | Strong | ||
basic prevention | 35. It is encouraged to carry out daily activities, adequate hydration, early limb movement on the side of catheter placement, and appropriate exercise to prevent thrombosis if possible [3] | JBI | 5b | Strong | |
Drug prevention | GRADE | B | Weak | ||
GRADE | B | Strong | |||
38. For specific children at increased risk of thrombosis, thromboprophylaxis with Low Molecular Weight Heparin (LMWH) for CRT prevention should be considered, such as children with ALL or lymphoma can be treated with prednisone/E. coli-asparaginase or a history of thrombotic events [13] | Diseases Society of America(IDSA)-United States | II | Strong | ||
GRADE | B | Strong | |||
40. For blocked CVADs, tPA should be used to restore patency. A second dose is recommended if the CVAD does not recover at least 30 minutes after local thrombolysis. If the CVAD remains blocked after two local thrombolytic agents, radiologic imaging is recommended to exclude CRT [32] | GRADE | C | Weak | ||
Imaging examination | JBI | 3a | Strong | ||
42. For the CRT diagnosis, CT or MRI should be performed as a second-line imaging test if ultrasound Doppler is not available or the results are unreliable or suspected to be falsely negative [13] | Diseases Society of America(IDSA)-United States | II | Weak | ||
Health education | GRADE | D | Strong | ||
44. It is recommended to educate children and their caregivers in the form of checklists on intravenous therapy in hospital or at home [33] | GRADE | D | Weak | ||
45. It is recommended to conduct targeted informed consent interviews and signatures for caregivers according to the different CVADs [33] | GRADE | D | Weak | ||
46. Caregivers should be trained. After training, caregivers should master how to care for the site, maintain patency, check for signs of infection and other complications, and seek help to solve problems [41] | CDC | C | Weak | ||
47. Preschool children should not be allowed to access to CVADs and any adults who will assist in the care of CVADs should attend a training course [41] | CDC | C | Weak | ||
48. The caregivers should be required to use a CVAD model and children to reveal complete care of the CVAD at least twice [41] | CDC | C | Weak | ||
Nursing records | 49. The type and name of CVAD, barcode, date of insertion, inserter, anatomical position, management, type and treatment of complications, and reason for and date of CVAD removal should be kept in the medical record [41] | CDC | B | Strong | |
50. It is recommended to keep a comprehensive record regarding all CVAD-related problems like infection, thrombosis and mechanical complications [41] | CDC | C | Weak | ||
Follow-up | 51. Guidelines should be developed and established at the treatment center for the ongoing management, tracking and follow-up of patients/families with CVADs [41] | CDC | B | Strong | |
52. Adherence to and knowledge of guidelines should be periodically evaluated in all patients with CVADs [41] | CDC | B | Strong | ||
53. The use of CVAD techniques by caregivers should be reassessed during a comprehensive visit. Appropriate care of the CVAD should be monitored more frequently and enhanced if catheter problems occur [41] | CDC | C | Weak | ||
54. Children requiring long-term CVADs should be followed-up regularly to reconsider the necessity of CVAD retention [38] | JBI | 3a | Strong | ||
55. In rapidly growing children, X-ray examination of catheter tip location may be warranted to monitor for poor positioning [41] | CDC | C | Weak | ||
CVAD removal | Removal indications | 56. Routine catheter removal is not recommended. Catheter removal should be considered when it is no longer needed for treatment, dysfunctional, positioning abnormal, combined with catheters related bloodstream infection, and with progressive CRT symptoms despite a standard anticoagulation treatment or in a condition of anticoagulation contraindication [3, 13, 30‐32] | GRADE | B | Strong |
GRADE | C | Weak | |||
Removal time | 58. To prevent thrombus from falling off, bleeding, and difficulty in removing, it is recommended to receive a period of anticoagulation, and then confirm there is no floating thrombus, thrombus, and the catheter does not adhere to the vascular wall by ultrasound before removal [3] | JBI | 5b | Strong | |
59. For children with CVAD in place who have a CRT and still requires the CVAD, we recommend that prophylactic doses of VKAs or LMWH after the initial 3 months of therapy can be given until the CVAD is removed. If recurrent thrombosis occurs while the child is receiving prophylactic therapy, we recommend continuing the therapeutic doses until the CVAD is removed and for a minimum of 3 months after the thrombosis [32] | GRADE | C | Weak | ||
Removal operation | 60. When the platelet count is above 50× 109/L, and the international normalized ratio (INR) is less than 1.5, the following procedure is recommended: firstly the child should take the supine position, and is guided to perform Valsalva during removal. After that, we suggest covering the puncture point with a closed dressing, then checking the integrity of the catheter removed. If a bloodstream infection related to the catheter is suspected, culturing the catheter tip should be performed. In case of difficulty in removal, experts in vascular surgery and intervention should be contacted for advice [33] | GRADE | D | Weak | |
61. Professionals who remove the catheter are required to be familiar with the fixation, length, allowable elastic deformation range, etc. of the catheter to prevent the catheter from breaking due to improper operation [3] | JBI | 5b | Strong | ||
Precautions in other special cases | 62. Removing a functional CVAD is not recommended in pediatric patients with symptomatic CRT who continue to require venous access [2] | GRADE | D | Weak | |
63. Removing the non-functional or unwanted CVADs is recommended for pediatric patients with symptomatic CRT [2] | GRADE | D | Strong | ||
64. It is recommended to delay removal of a CVAD until after initiation of anticoagulation for days, rather than immediate removal in pediatric patients with symptomatic CRT who no longer require venous access or in whom the CVAD is nonfunctional [2] | GRADE | D | Weak | ||
65. For children with large (> 2 cm) movable right atrial thrombosis, anticoagulation, with appropriately timed CVAD removal, and consideration of surgical intervention or thrombolysis are suggested based on individualized risk-benefit assessment [32] | GRADE | C | Weak | ||
Treatment of difficulty in removal after CRT | 66. First of all, giving up the plan of immediate catheter removal, actively finding out the reasons, and providing sufficient psychological support for children and (or) long-term caregivers. Trying to use rest, posture change, hot compress, and vasospasmolytic drugs to remove the catheter. During the removal process, additional strength is allowed, but violence is not allowed. If the catheter cannot be removed after many attempts, the vascular surgeon or interventional physician shall be invited to consult and decide whether to cut or remove the catheter under the guidance of digital subtraction angiography in combination with imaging examination [3] | JBI | 3a | Strong | |
Others | 67. If a new catheter needs to be inserted, the status of the superior venous system must be assessed by ultrasound Doppler or ultrasound scan [13] | Infectious Diseases Society of America(IDSA)-United States | III | Weak | |
68. CRT prevention in children should not be separated from overall VTE prevention. For children at a high risk of CRT, it is still necessary to take corresponding preventive measures against the risk factors of VTE [3] | JBI | 5b | Strong recommendation |